The investment will cover the acquisition of 2,265,100 doses through the award of 23 lots. These lots guarantee the supply for the region's immunization schedules over the next two years.
Included among the vaccines are the hexavalent vaccine (protection against hepatitis B, diphtheria, tetanus, acellular pertussis, inactivated polio, and Haemophilus influenzae type b), the combined vaccine against diphtheria, tetanus, acellular pertussis, and inactivated polio, and the specific vaccine against Haemophilus influenzae type b. Doses with reduced antigenic content against diphtheria, tetanus, and acellular pertussis are also included.
Additionally, vaccines against hepatitis B for pediatric and adult populations, including at-risk groups, and against hepatitis A for all ages have been awarded. Quantities range from 8,800 units for the rabies vaccine to 325,000 for the conjugate vaccine against meningococcus B.
The contract also includes doses for the prevention of measles, rubella, and mumps; against varicella; combined against measles, rubella, mumps, and varicella; conjugate vaccines for meningococcus C and serogroups A, C, and W; against meningococcus B; against rabies, and against herpes zoster.
Since 2021, the region has had a comprehensive vaccination calendar covering from the prenatal period up to 18 years of age, also including adults up to 60 years old.




